Recovery here is not wound healing. It is the body clearing a controlled injury. Deoxycholic acid ruptures fat-cell membranes, and the debris has to be removed by inflammation. The recovery is the treatment finishing its job, which is why the timeline is measured in weeks rather than days, and why some of what you feel afterwards is a sign it worked.
There is no downtime figure in the label and none on the manufacturer's patient site. What exists is incidence and duration data for each individual effect, and one study that recorded missed work. Everything below is one of those.
Sessions are at least a month apart under the label, so recovery is not a single event. It repeats, and it gets easier: an adverse event followed 94.4 per cent of first sessions and 46.4 per cent of sixth sessions, with severity falling as well.
This is the effect most likely to surprise you: Two thirds of treated patients in the trials had numbness under the chin, at 66 per cent against 6 per cent on placebo. The median duration in the pooled trial analysis was 43 days — six weeks. Forty-two per cent of all treated patients still had it more than 30 days after a session, which is a higher figure than for any other effect including swelling.
Real-world numbers are shorter. A prospective series of 100 consecutive private-practice patients reported a mean of 27.9 days, plus or minus 11.3. Those patients had fewer sessions on average than trial protocol allowed.
A separate, differently coded effect, pins and needles, occurred in 14 per cent with a median of 10 days. Numbness of the mouth and lips has been reported since the drug went to market.
The likely reason is straightforward. This is a detergent, and myelin — the fatty sheath around nerves — is lipid-rich. An experimental rat study injecting the drug in and around the sciatic nerve was designed on exactly that reasoning. Nothing published tells you how to shorten it. In the trials it resolved on its own.
Worth separating from a real complication: numbness is loss of sensation. Being unable to move part of your lower face is a different thing, and it belongs in the section on nerve injury below.
Bruising affected 72 per cent of treated patients — and 70 per cent of people who received placebo injections. That near-identical rate is the clearest evidence in the dataset that bruising is the needles and the volume, not the drug. A session can involve up to 50 injections on a one-centimetre grid, and the trial median was 27 injections. The median duration was 9 days in both groups.
If you take an antiplatelet drug or a blood thinner, or have a bleeding condition, the label says the drug should be used with caution. That is a conversation to have before you book, not on the day.
Pain is a different picture: 70 per cent of treated patients against 32 per cent on placebo, so most of it is the drug. Median 7 days, and 16 per cent still reported it past 30 days. Tenderness in the real-world series averaged 3.5 days. The label mentions ice or cold packs and topical or injected local anaesthetic to make the injections themselves more comfortable. A real-world protocol used ice before treatment, for 15 minutes after, then 10 minutes on and 10 minutes off for 48 hours with paracetamol, and the author noted that adherence past the first 24 hours was generally poor.
Firm, thickened tissue affected 23 per cent of treated patients against 3 per cent on placebo, with a median of 28 days, and 13 per cent still had it past 30 days. Distinct lumps affected 13 per cent against 3 per cent, median 23 days. These are the slowest of the common effects to resolve, and they often outlast the visible swelling.
The tissue findings line up. At 28 days after injection, samples show inflammation largely resolved but the fibrous partitions running through the fat thickened, with new small blood vessels and shrunken fat lobules. A firm area at four weeks is consistent with that stage, not with something going wrong.
"Injection site mass" is listed among effects reported after the drug went to market, where no rate can be calculated. A published case report describes chronic infection with lump formation after a deoxycholate injection, which is a reminder that a lump that is hot, red, growing or painful is a different problem from one that is simply firm.
This is the honest part. One controlled study of any recovery measure after this drug has been published, and it is a single-centre, double-blind pilot in which a commercial topical product was compared with a bland moisturiser twice daily after treatment. Investigator-assessed swelling and firmness were lower with the product at weeks 1 and 2, an objective firmness measurement was significantly lower at week 2, and participants reported less tenderness. It is a pilot, it is single-centre, and the product has a commercial interest in the outcome.
Everything else commonly recommended — ice or cold packs afterwards, compression garments and chin straps, antihistamines, oral steroids, anti-inflammatories, sleeping propped up, massaging the area — has no published controlled evidence in Kybella patients. Not disproven. Untested. The label endorses ice only for comfort during the injections themselves.
Two things do have data behind them. Reducing the injected volume reduces what follows: the pooled analysis links swelling and difficulty swallowing to volume, and injected volume fell at every successive session in the trials as there was less fat to treat. And waiting is effective: the pooled analysis authors summarise that injection-site reactions typically resolved within 14 days without medication or procedures.
Massage deserves one caution. Nothing published supports or forbids it, but the treatment area sits over the marginal mandibular nerve zone and over the salivary glands and lymph nodes the label tells injectors to avoid. Ask your provider rather than deciding on your own.
The only citable downtime figures come from a 12-month open-label study of 165 people. In the seven days after the first treatment, 13.3 per cent missed work and 33.9 per cent missed social or leisure activities. After later treatments those fell to 2.4 to 6.0 per cent and 10.0 to 15.7 per cent.
No study recommends a number of days off: What the data support is planning around the first session specifically, and expecting each subsequent one to be easier.
The other number worth knowing before you commit to a course: 7.4 per cent of treated patients in the pooled trials stopped treatment because of a side effect, against 1.2 per cent of placebo patients.
Marginal mandibular nerve injury: This nerve controls the muscles that pull the lower lip down. Injury shows up as an uneven smile or weakness on one side of the lower face. It occurred in 4 per cent of treated patients in the trials, against under 1 per cent on placebo. Because most patients had several sessions, the per-session figure is the more useful one: about 1 per cent of sessions. Every case in the trials resolved on its own — median 44 days, with a reported range of 1 to 298 days. The label defines an avoidance zone: do not inject above the lower border of the jawbone, and do not inject within a 1 to 1.5 cm band below it running from the jaw angle to the chin.
Difficulty swallowing: Two per cent of treated patients. The label attributes it to the swelling, pain and firmness under the chin rather than to nerve damage. Cases resolved on their own with a median of 3 days and a longest report of 81 days. People with any history of swallowing difficulty were excluded from the trials, and the label says to avoid the drug in them.
Ulceration and tissue death: The label states plainly that injections that are too superficial, into the skin rather than the fat, may cause skin ulceration and tissue death, and instructs the injector not to withdraw the needle during an injection for the same reason. In the pooled trials this happened once in 515 treated patients — a mild event that resolved within 23 days, which the authors attributed to inappropriate injection technique. Ulceration, tissue death, infection and scarring are all listed among effects reported after the drug went to market. Some reported infections have included cellulitis and abscesses requiring intravenous antibiotics and surgical drainage. This is a technique complication, which is a reason to care who is holding the syringe.
Hair loss at an injection site: This has its own warning in the label, which says the onset and duration vary and that it may persist — the label does not promise regrowth, and advises withholding further treatment until it resolves. In the pooled trials it affected 0.4 per cent of treated patients, median 151 days, and 0.6 per cent of placebo patients, median 272 days. The placebo rate being numerically higher is genuinely odd and worth knowing. Individual case reports of hair loss after these injections have been published, and in an off-label series treating jowls, 3 of 66 patients had it and all resolved.
One thing this drug does not have is a boxed warning: Its safety content sits in the ordinary warnings section of the label.
Say if you have ever had difficulty swallowing, even briefly and even years ago. Those patients were excluded from the trials and the label says to avoid the drug in them.
Say if you take a blood thinner or antiplatelet medicine, or bruise very easily. Bruising affected roughly seven in ten people in the trials and the label calls for caution here.
Ask what the fullness under your chin actually is. The label instructs the prescriber to screen for other causes, naming an enlarged thyroid and enlarged lymph nodes, and to think carefully before treating people with loose skin or prominent neck bands.
Ask who is injecting, how many millilitres are planned, and how they mark the nerve avoidance zone. The two things that most reliably go wrong — nerve injury and ulceration — are both about where the needle goes. Injections must not go above the lower border of the jaw, and the drug must not be diluted or mixed with anything.
The one absolute contraindication in the label is an infection at the injection sites. If you have a spot, a sore or an infection in the area, the session should be postponed.
Plan for the first session to be the worst, and to be at least a month before anything you care about looking well for.
Difficulty swallowing, or a feeling that your throat or airway is closing
Difficulty breathing
Fever with spreading redness, warmth or pus from the treated area. Infections reported after these injections have included cellulitis and abscesses requiring intravenous antibiotics and surgical drainage
Your smile becomes uneven, or you cannot move your lower lip normally on one side
Any part of your face feels weak rather than numb
An open sore, a blister, a dark or dusky patch, or drainage appears at an injection site
Swelling, redness or pain is increasing after about day three instead of settling
A lump is hot, red, growing or painful, rather than simply firm
Hair thins or disappears in the treated area
Numbness is still present after about two months, or is spreading
You felt faint or lightheaded during or after the injections
Swallowing feels uncomfortable but not frightening. Mention it before the next session, because it is linked to the volume injected